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ABSTRACT: With advances in knowledge disease,
boundaries may change. Occasionally, these changes are
of such amagnitude that they require redefinition of the dis-
ease. In recognition of the profound changes in our under-
standing of Parkinson’s disease (PD), the International
Parkinson and Movement Disorders Society (MDS) com-
missioned a task force to consider a redefinition of PD. This
review is a discussion article, intended as the introductory
statement of the task force. Several critical issues were
identified that challenge current PD definitions. First, new
findings challenge the central role of the classical patho-
logic criteria as the arbiter of diagnosis, notably genetic
cases without synuclein deposition, the high prevalence of
incidental Lewy body (LB) deposition, and the nonmotor
prodrome of PD. It remains unclear, however, whether
these challenges merit a change in the pathologic gold
standard, especially considering the limitations of alternate
gold standards. Second, the increasing recognition of
dementia in PD challenges the distinction between diffuse
LB disease and PD. Consideration might be given to
removing dementia as an exclusion criterion for PD diagno-
sis. Third, there is increasing recognition of disease hetero-
geneity, suggesting that PD subtypes should be formally
identified; however, current subtype classifications may
not be sufficiently robust to warrant formal delineation.
Fourth, the recognition of a nonmotor prodrome of PD
requires that new diagnostic criteria for early-stage and
prodromal PD should be created; here, essential features
of these criteria are proposed. Finally, there is a need to cre-
ate newMDS diagnostic criteria that take these changes in
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Since the original description of Parkinson’s disease
(PD), there have been radical changes in our conceptuali-
zation of the disease, starting with a better understand-
ing of motor manifestations, clear pathologic
definitions, and availability of therapy that is so reliably
effective as to be part of diagnostic criteria. Moreover,
our understanding continues to develop, with increasing
knowledge of nonmotor aspects, recognition that neuro-
degeneration can start before motor symptoms manifest,
better understanding of genetics and environmental fac-
tors, and progress toward developing reliable bio-
markers and animal models. With these advances,
clinicians and specialists in genetics, epidemiology,
pathology, and basic science have developed their own
conceptualizations of disease; each valid, but none repre-
senting the whole truth. Can these conceptualizations be
united under one umbrella definition?
To deal with the challenges of disease definition, the
International Parkinson and Movement Disorder Soci-
ety (MDS) convened a task force to generate an
updated definition of PD. The group identified three
critical issues: (1) Who decides what is PD and what is
the gold standard for a “final” diagnosis? (2) What
clinical features fit under the PD umbrella? Should sub-
types be incorporated into the diagnosis? Should some
diagnostic entities be held distinct (e.g., dementia with
Lewy bodies; DLB)? (3) Defining disease onset—can
PD be defined before classic motor features develop?
This review is intended as an introductory discus-
sion article; it is not the final word on disease defini-
tion, but rather an opening of dialog. Each section
will start by presenting conversational-style informal
minivignettes (in italics) that summarize what clini-
cians or researchers often mention when pointing out
problems with the current PD definition. Both sides of
each issue are then discussed, followed by proposals
for moving forward. Finally, we will discuss the need
for new diagnostic criteria for PD.
What Is the Gold Standard for the
Definition of PD?
The issue: A patient with classic clinical PD died with-
out autopsy; can one never say they are “sure” she had
PD? Why is autopsy the gold standard if it is almost
never available (and might become outdated, once we
have good biomarkers). Furthermore, don’t genetic stud-
ies suggest that pathology can be inconclusive? A patient
from a family of pathologically confirmed LRRK2 PD
who meets clinical criteria for PD, but has no Lewy
bodies (LB) on autopsy, or patients with parkin muta-
tions without LB; do they not have PD?
What we currently consider as the gold standard for
PD diagnosis is not always explicit. Nevertheless, most
clinicians would endorse the diagnostic gold standard
as a combined clinical and pathological syndrome,
consisting of the following:
1. A motor clinical syndrome, with levodopa-
responsive parkinsonism, typical clinical charac-
teristics, and an absence of markers suggestive of
other disease.
2. Pathologic confirmation of a-synuclein (a-Syn)
deposition and dopamine neuronal loss in the
substantia nigra pars compacta (SNpc). Only at
this point is the diagnosis termed “definite.” If
typical synuclein pathology is not found, the clin-
ical diagnosis is considered incorrect. Likewise,
the pathology is “incidental” in the absence of
clinical symptoms or attributed to another disease
if parkinsonism did not dominate the clinical pic-
ture (e.g., DLB or primary autonomic failure).
Therefore, a motor clinical syndrome is the entry
point, and pathology is the arbiter of diagnosis. Patho-
logic findings ultimately feed back into clinical criteria
by correcting clinical diagnoses.
Challenging the Status Quo
Several challenges have been raised against the
requirement for both SNpc neurodegeneration and a-
Syn deposition as essential features and, more glob-
ally, of pathology’s role as the ultimate arbitrator.
These include the following:
1. Genetic/pathologic correlation: Although, in
many patients, leucine-rich repeat kinase 2
(LRRK2) mutations are associated with classic a-
Syn deposition,1,2 there are nonetheless reports of
members of the same family having different
pathologies, some without a-Syn deposition. LB
are absent in 21% of G2019 mutations and
>50% of non-G2019S mutations.2 With parkin,
most meet clinical PD criteria, have SN degenera-
tion on autopsy, but have little or no a-Syn depo-
sition2 (exceptions were older and may have had
coincidental “incidental LB”). We must also take
into account the uncertain role of a-Syn aggrega-
tion (possibly protective) versus a-Syn oligomers
(toxic) in PD pathogenesis. As a hypothetical
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illustration, imagine a genetic mutation that pre-
vents aggregation of “toxic” a-Syn oligomers
into “protective” LB; this mutation would reca-
pitulate the PD pathogenic process, without
a-synuclein deposition on autopsy.
2. SNpc loss is not the only pathologic feature and
may not occur first: The premotor/prodromal
syndrome must also have a pathologic correlate
(see “The Beginning of PD” below).
3. a-Syn pathology may not determine clinical
symptoms: On autopsy, approximately 15% have
incidental LB, 5 times the prevalence of clinical
LB diseases.3-6 If a-Syn pathology defines disease
alone, must all these patients be considered
asymptomatic PD?
4. a-Syn aggregates may not be the first pathology:
Lewy pathology may develop relatively late, with
presynaptic dysfunction being the first abnormal-
ity.7-9 Might current pathologic criteria miss early
stages of PD?
5. Pragmatic considerations: Autopsy is performed
only at the end of life (not useful diagnostically dur-
ing life), and only few have pathologic confirmation.
Potential alternate gold standards for diagnosis
could include the following:
1. Clinical diagnosis alone: James Parkinson did not
define a pathologic diagnosis, but a clinical syndrome.
This clinical syndrome is readily recognized and,
despite interindividual variability, very characteristic.
Patients experience clinical disease, not pathology,
and clinical criteria contain the features important to
patients, including response to treatment.
2. Genetics: If experience with parkin- and LRRK2-
related parkinsonism suggests that pathology can
be inconclusive, can genetics ultimately define
diagnosis?
Defending the Status Quo
Despite these issues, are there reasons to keep our
current clinicopathologic standard?
1. Alternate gold standards also have limitations:
i. Clinical: Defining PD solely on a clinical basis
is circular; you can never be wrong. If clinical
diagnosis is the gold standard, a patient who
meets clinical criteria has PD regardless of
autopsy findings. What of patients with clini-
cal PD diagnosis who have clear pathology of
alternate diagnoses, such as MSA or PSP?
ii. Genetics: Well under 10% of PD patients cur-
rently have a genetic explanation. Moreover,
whereas new genetic causes may be defined, herit-
ability is relatively low; most monozygotic twins
are discordant.10,11 Also, if genes are inpenetrant,
interpreting a positive genetic test as diagnostic
can be incorrect. Finally, genetic mutations may
result in heterogeneous clinical phenotypes, not
just heterogeneous pathology; for example,
LRRK2 mutations are also associated with motor
neuron disease.12 If a LRRK2 carrier had classic
clinical motor neuron disease, would genetic cri-
teria mandate diagnosis of PD?
2. Although pragmatic considerations imply that
pathological diagnosis is not useful for an indi-
vidual, pathology can nonetheless serve as an
ultimate reference by which clinical criteria are
tested. Furthermore, if biomarkers of both a-Syn
deposition and SNpc degeneration become suffi-
ciently reliable, these could ultimately replace
autopsy confirmation.
3. Parkin and similar mutations might have a differ-
ent underlying pathogenesis than sporadic PD.
Moreover, these patients often have important
clinical differences (e.g., earlier age of onset). It
thus might be entirely appropriate to consider
them separate diseases or a subcategory of PD.
4. Finally, it should not be forgotten that the vast
majority (95%) of patients who fulfill clinical
criteria have classic a-Syn pathology. Moreover,
when the clinical diagnosis is “wrong,” there is
usually a clear alternate pathologic cause (PSP,
MSA, and so on). If we let exceptional cases
drive our definition, do we “throw out the baby
with the bathwater?”
Moving Forward
The task force proposes the following:
1. The core clinicopathologic criteria of a clinical
motor syndrome accompanied by SNpc neurode-
generation and synuclein deposition remain a
gold standard of PD diagnosis. In the future,
should reliable biomarkers of synuclein deposi-
tion be developed, these can be used to indicate a
likely gold-standard clinicopathologic diagnosis.
2. To incorporate genetic findings under the PD
umbrella, a separate “clinicogenetic” category
should be created to diagnose PD, regardless
of the occurrence of synuclein deposition. This
category would refer specifically to highly pene-
trant mutations in which the majority of affecteds
meet clinical PD criteria, regardless of whether
autopsy specimens of patients with this mutation
find a-Syn pathology. In research studies, this
diagnostic subcategory could be included or not
according to the context. For example, an
autopsy study validating clinical diagnostic crite-
ria might exclude such patients, a randomized
trial of symptomatic dopaminergic therapy might
include them, and a neuroprotective trial may
elect to include or exclude, depending upon the
mechanism of the agent.
B E R G , P O S T U M A E T A L .
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3. A new scheme is likely needed to replace the
current PARK classification, which is under con-
siderable strain. This scheme should specifically
differentiate between causative genes and risk fac-
tors, consider the predominant phenotype, and—
in the long run—admit the incorporation of pro-
tective variants.13 A dedicated task force of the
MDS is currently working on this complex issue.
What Features Fit Under the PD
Umbrella?
DLB
The issue: A patient developed cognitive impairment
18 months after PD diagnosis; he has PD dementia
(PDD). Another developed cognitive impairment 10
months after PD diagnosis; according to current defi-
nitions, the initial diagnosis was “wrong,” and she has
DLB. Does this make sense?
As diagnostic criteria currently stand, dementia devel-
oping before the second year of parkinsonism is an
exclusion criterion for PD; the diagnosis is DLB.14-16
If dementia starts after 1 year, the diagnosis is PDD.
Challenging the Status Quo
Beyond the arbitrary nature of the 1-year rule, there
is increasing controversy about whether the distinction
itself is valid. Briefly, the challenges are16 as follows:
1. Similar dementia presentation, with hallucina-
tions, fluctuations, neuroleptic sensitivity, and
rapid eye movement sleep behavior disorder
(RBD) in both.16,17
2. Similar neuropsychological findings, with pre-
dominant visuoperceptual impairment, improve-
ment of memory with cueing, and so on.16
3. Similar nonmotor profile, with olfactory loss,
depression, autonomic dysfunction, and sleep dis-
orders in both.
4. Similar imaging, with overlapping patterns of
cortical atrophy, glucose utilization, neurotrans-
mitter changes,18 and diffusion tensor imaging.19
5. Similar prodromal stage: For example, patients
with idiopathic RBD develop both syndromes, with
little difference in clinical evolution patterns.20
6. Similar genetics: For example, family members
with a-Syn duplications or triplications as well as
glucocerebrosidase mutations can present with
either condition.
7. Similar pathology: Patients in both groups dem-
onstrate a-Syn pathology in both the brainstem
and cortex.
Implicit in this discussion is the conceptualization of
DLB, which shares clinical and pathological features
of Alzheimer’s disease (AD) and PDD. This overlap
has created tension in naming the condition, with evo-
lution from “Lewy body variant of AD,” to “Lewy
body dementia,” to the current “dementia with Lewy
bodies.”
Defending the Status Quo
There are several reasons to consider retaining the
current distinction:
1. Although not universally specific, there are imag-
ing differences between PDD and DLB, including
degree of amyloid deposition, cholinergic loss,
vascular damage, single-photon emission CT/PET
hypoperfusion, and atrophy patterns.16,21
2. Parkinsonism in DLB can differ from idiopathic
PD, typically with less tremor and L-dopa
response.22 Many parkinsonian DLB patients
would not meet criteria for clinical PD.
3. Although patients with DLB and PDD look simi-
lar at end stage, the course can be extremely dif-
ferent. A counterexample to the vignette: A
patient diagnosed as AD with a severe amnestic
disorder eventually develops visual hallucinations,
cognitive fluctuations, and mild parkinsonian
signs (DLB). Another patient has typical PD with
normal cognition for many years and eventually
develops hallucinations and cognitive decline
(PDD). Are these patients not distinct?
Moving Forward
Despite the controversy, most agree that there is
important clinicopathologic overlap between these con-
ditions. Perhaps in DLB and PDD, there is a continuum
between relatively “pure” a-Syn pathology and a pre-
dominant Alzheimer (6 vascular) pathology (Fig. 1).
Most DLB patients will develop parkinsonism and
most PD patients will develop dementia, but onset time
differs. At one extreme are patients with young-onset
classic PD who remain dementia free for most of their
long disease course; if they eventually dement, cortical
pathology would be predominantly LB, with sparse AD
pathology. At the other extreme are patients who first
develop dementia and manifest parkinsonism very late
or never during life; these patients would have more
AD pathology (6 vascular pathology) with less LB dep-
osition. Between these extremes lie the majority of
patients. If a continuous spectrum exists, the advan-
tages of categorical division are debatable.
Therefore, the task force proposes the following:
Consider omitting the “1-year” rule, which sepa-
rates PDD and DLB. Rather, when a patient presents
with motor signs and meets full clinical criteria for
PD, the diagnosis of PD is applied, regardless of pres-
ence or timing of dementia. In other words, dementia
is no longer an exclusion criterion for PD. For those
patients who already carry a DLB diagnosis (according
T I M E T O R E D E F I N E P D
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to consensus criteria23), the diagnosis can optionally
be qualified as “PD (DLB subtype).”
Note that this proposal would not invalidate the diag-
nostic category of DLB. In clinical communication with
patients with the DLB subtype, the diagnostic term DLB
could continue to be used. Moreover, the classification
of patients with DLB diagnosis who do not have par-
kinsonism, or whose parkinsonism does not not meet
PD criteria (e.g., no response to dopaminergic medica-
tions), would not be affected by this definition change.
PD Subtypes
The issue: A patient had unilateral tremor onset at
age 40, robust L-dopa response with fluctuations and,
20 years later, has few nonmotor features. A second
developed bilateral bradykinesia and rigidity at age 80
and had no fluctuations, but had severe constipation,
urinary dysfunction, sleep disturbance, and depression,
eventually dying with dementia. Do these patients
have the same disease?
Challenging the Status Quo
PD has considerable variability in rate of progres-
sion of motor manifestations and prevalence of non-
motor manifestations. This can question the
conceptualization of PD as a unitary disorder. At min-
imum, it suggests that PD may be divisible into sub-
types. Currently, no formal subtype classification
exists and subtypes have not been generally incorpo-
rated into research protocols.24
Most attempts to classify subtypes rely upon one of
two approaches. One uses data-driven approaches with
cluster analysis to identify subtypes in a hypothesis-free
manner.25-32 In these studies, clusters have been defined
based on age, motor features, and, possibly, a nonmotor
symptom cluster.26 These variables correlate with differ-
ent mortality, progression, motor complications, demen-
tia, and behavioral symptoms. The second approach
classifies subgroups on a single factor and looks for dif-
ferences between groups. Two commonly suggested sub-
types are onset age and tremor dominance. Age
subtyping is proposed because young patients have
more robust L-dopa response, more motor complica-
tions, and fewer cognitive disturbances.33-35 Tremor-
predominant subtypes are proposed because they may
have better prognosis and fewer cognitive disturban-
ces.33-35 Other studies suggest other potential subtype
identifiers; for example, olfactory loss correlates with
cognitive impairment,36 and RBD correlates with auto-
nomic dysfunction and higher dementia risk.37,38 In the
future, it may also be possible to subdivide PD accord-
ing to pathogenic mechanism (mitochondrial predomi-
nant, inflammatory predominant, and so on).
Defending the Status Quo
1. Regardless of the dramatic differences in clinical
manifestations, most patients with PD have a char-
acteristic pathologic substrate, suggesting that a
unifying diagnosis is appropriate. Moreover, many
other diseases have dramatic differences in clinical
severity and manifestations.
2. Current subtypes may not impact much upon dis-
ease course. Some studies find that tremor has little
effect on prognosis.32,34 Where there are differen-
ces, there are potential confounds, including diag-
nostic sensitivity (tremor-dominant patients are
diagnosed earlier, so prognosis appears better for
disease duration), or misdiagnosis (patients misdiag-
nosed as tremor-predominant PD have relatively
benign alternate diagnoses, such as essential tremor,
versus akinetic-rigid syndrome alternate diagnoses,
such as MSA or PSP). Age is continuous, and defin-
ing robust cutoffs is not simple. For example,
young cutoffs (e.g., <40) help identify genetic
mutations, but represent only a small proportion of
PD patients (<1%).39,40 Criteria for “old-onset”
PD may also be needed, because older patients have
worse prognosis, higher mortality, more dementia,
FIG. 1. Simplified model of how the type of cortical pathology and clinical presentation of PDD and DLB might interact. Dementia in DLB/PD is
associated with two major pathologies: synucleinopathy (i.e., Parkinson pathology) and neuritic amyloidopathy (i.e., Alzheimer pathology). In PD
patients who develop dementia very late in their illness, or not at all (far left), neuritic amyloid deposition is minimal (or absent), and cortical pathol-
ogy is mainly that of a-Syn deposition. At the other extreme, DLB patients with predominant neuritic amyloid deposition and very minimal a-Syn
deposition would usually be diagnosed as AD during life, developing clinical DLB hallmarks late (if at all). Between these two extremes of the spec-
trum lie the most patients with PD and DLB. This hypothetical spectrum is not meant to be exclusive—other factors may also be important in deter-
mining dementia onset (e.g., “top down” vs. “bottom up” a-Syn deposition, degree of vascular pathology, and so on).
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and more mixed pathology. Finally, current age,
rather than onset age, may be the critical factor
influencing disease manifestations.
Moving Forward
In summary, there is no doubt that PD has consider-
able heterogeneity in clinical presentation and progno-
sis. The task force proposes the following:
1. Clinical subtypes should only be delineated if
there are clear data that demonstrate consistent,
large differences in prognosis, predicted disease
manifestations, or treatment. Currently, it is
unclear whether any of the current subtype classi-
fications qualify.
2. The search for subtypes should not be restricted
to clinical features, but should include subtypes
of molecular pathogenesis.
The Beginning of PD
The issue: A patient has RBD, olfactory loss, consti-
pation, and depression, but no parkinsonism. Dopami-
nergic neuroimaging and SN ultrasound are abnormal.
Doesn’t this patient have PD?
Challenging the Status Quo
It has become clear that neurodegeneration in PD
likely begins years or decades before full PD diagnosis
can be made.41 In this phase, nonmotor manifestations,
such as RBD, hyposmia, autonomic dysfunction, visual
disturbances, and depression, often occur. This has
important implications for defining PD. The patient
described above almost certainly has neurodegeneration
with a-Syn pathology and therefore, in some sense,
“has” PD. If so, should our definition be changed?
Defending the Status Quo
Before adding early stages to a formal PD definition,
the following caveats should be noted:
1. Autopsy studies find incidental LB disease in
15% of the elderly, but only a minority manifest
clinical symptoms. This suggests that there may
be compensatory mechanisms that forestall pro-
gression, so transition to clinical PD may not be
inevitable.
2. Most premotor signs are nonspecific (e.g., olfac-
tory dysfunction,42 constipation,43 and SN hyper-
echogenicity44), reducing accuracy of early
diagnosis.
3. Neurodegeneration in PD may not universally
start outside the SNpc. Moreover, not all PD
patients have nonmotor features, especially in
early motor stages.
4. Given that PD definition has always centered on
a motor syndrome, changing the definition to
include patients without motor signs is a major
shift. It would radically change communication
with patients, estimates of disease prevalence,
and so on. For continuity with historical stand-
ards, it may be preferable to retain the motor
syndrome in “classic” PD diagnosis and delineate
prodromal stages separately.
Moving Forward
Regardless of the caveats listed above, there is little
question that many patients have a preclinical/prodro-
mal stage of their disease, which should be incorpo-
rated in the definition of PD.45,46 The task force
proposes the following:
1. Clinical diagnosis of classic PD should remain
centered on a motor syndrome. Separate
research-based criteria should be developed to
allow diagnosis of early PD stages.
2. For delineation of early stages, disease should be
classified as “preclinical” and “prodromal.” Pre-
clinical refers to the presence of neurodegenerative
synucleinopathy without clinical symptoms (i.e.,
defined by biomarkers; note that this stage cannot
be currently diagnosed because reliable biomarkers
are not available). Prodromal refers to the pres-
ence of early symptoms and signs before the classi-
cal PD diagnosis is possible. This prodromal term
makes no assumptions about the order in which
motor versus nonmotor symptoms develop.
3. Because one cannot determine whether any patient
with prodromal neurodegenerative synucleinop-
athy will eventually progress to full clinical PD,
the definition of prodromal PD should center
upon the likelihood of a neurodegenerative synu-
cleinopathy being present, regardless of
“conversion rate” to full clinical PD.
4. Although PD, by definition, passes inevitably
through some type of prodromal phase, there
are currently no 100% reliable means to identify
prodromal PD. Therefore, diagnostic criteria for
prodromal PD will necessarily be probabilistic.
We propose two levels of certainty. Probable
prodromal PD would refer to a high likelihood
(e.g., >80%; sufficiently certain for neuroprotec-
tive trials). Possible prodromal PD would refer
to a lower, but still substantial, likelihood of
neurodegenerative synucleinopathy (e.g., 30%-
80%).
5. Prodromal PD criteria should incorporate clinical
motor markers, clinical nonmotor markers, and
nonclinical biomarkers. Inclusion of a marker into
prodromal criteria should generally require pro-
spective studies documenting predictive value for
full clinical PD. Markers should be divided into
categories of specificity, such that high specificity
T I M E T O R E D E F I N E P D
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markers carry more weight than those with lower
specificity. Criteria should also incorporate risk,
adjusting probability estimates for persons with
documented high-risk states (e.g., carriers of
genetic mutations).
From Definition to Diagnostic
Criteria
When a disease definition changes, its diagnosis
inevitably changes with it. Therefore, creation of a
new definition provides an opportunity to develop
new clinical diagnostic criteria. There are several rea-
sons to develop new clinical diagnostic criteria:
1. No standard clinical criteria exist. Many criteria
have been proposed for PD,45-52 but none have
been developed or adopted by an international
organization such as the MDS.
2. New knowledge: Diagnostic criteria must accom-
modate new findings. For example, it is no longer
appropriate to consider having affected family
members or autonomic dysfunction as exclusion
criteria.46,53 Moreover, the systemic character of
the disease needs to be acknowledged, especially
incorporating nonmotor symptoms.54
3. Changes in health care or disease patterns:
Exclusion criteria for patients taking neuroleptic
medications45 require rewording, given develop-
ment of atypical neuroleptics such as clozapine
and quetiapine. Similarly, excluding patients with
encephalitis lethargica47,55 may not be relevant as
this epidemic passes into history.
4. Changes in definition that change diagnosis: For
example, if early dementia is permitted, exclusion
criteria targeted at cognitive impairment would
be removed.
How then might future diagnostic criteria look? In
developing criteria, some key aspects must be
considered:
1. Clear definition of the motor syndrome: If the
motor syndrome remains central to diagnosis,
parkinsonism itself must be clearly defined. Sev-
eral large-scale studies have documented mild
parkinsonian syndromes in 25% to 50%
of elderly persons without clinical features of
PD56-59 or a-Syn deposition57,60; these must be
distinguished from PD. Moreover, thresholds
must be delineated to define parkinsonism
“conversion” from prodromal stages.
2. Clinical expert as benchmark: 75% to 95% of
patients diagnosed by experts during life have PD
confirmed on autopsy, and more recent studies usu-
ally find better accuracy.55,61,62 Of note, experi-
enced clinicians may diagnose PD with even greater
accuracy than formal diagnostic criteria, perhaps
because clinicians interpret exclusion criteria in
context.61,63 If clinical expert opinion is the gold-
standard diagnostic technique in life, then diagnos-
tic criteria should attempt to codify the diagnostic
process of an expert clinician. Criteria should sys-
tematize this process, so that it can be reproducible
between clinicians (essential in research studies)
and applied by clinicians with less expertise.
3. Diversity of criteria types: Imitating the diagnostic
process of an experienced clinician involves incor-
porating numerous factors. First, clinicians assess
both negative features that argue against PD and
positive features that argue for PD. Second, not all
features are of equal weight. Some negative fea-
tures are so specific that they are incompatible
with PD. Other features suggest a possible alter-
nate cause, but are insufficient by themselves to
preclude diagnosis. Third, rather than following a
“recipe” to make diagnoses, experienced clinicians
allow for flexibility in application of exclusion cri-
teria, particularly if there are clear extenuating cir-
cumstances or complex situations that alter the
significance of a criterion.
4. Time: Diagnostic accuracy increases with time;
early in disease progression, response to treatment
is less defined, and hallmarks of other neurodege-
nerative diseases may not have emerged. Also,
some “atypical” features are incompatible with
diagnosis early in disease, but may be a late fea-
ture in otherwise typical PD.
5. Grades of certainty: Overemphasis on avoiding
false-positive diagnoses means missing many
patients with true disease, whereas overemphasis
on detecting all PD patients leads to false-positive
diagnoses. The importance of false negatives ver-
sus false positives varies according to the purpose
for which criteria are applied. For example, in a
randomized, clinical trial, ensuring high specificity
of PD diagnosis is key, and incorrect exclusion of
true PD cases is arguably less critical (although
excessive exclusion creates generalizability bias).
By contrast, for natural history studies and epide-
miologic research, diagnostic specificity and gener-
alizability are both critical; one must balance false
positives and false negatives.
6. Ancillary testing: Currently, PD diagnoses are
generally made clinically, without requiring
additional diagnostic tests. Any criteria should be
applicable across a broad range of settings, and
demanding specific ancillary diagnostic testing
reduces generalizability and utility of the criteria.
However, in certain contexts, ancillary diagnostic
testing is used, particularly in resolving uncertain
cases. Moreover, as knowledge advances, diag-
nostic biochemical markers, neuroimaging, or
means to document a-Syn deposition may
become clinically available.
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Therefore the task force proposes the following:
1. Formal MDS diagnostic criteria should be created
for the diagnosis of clinical PD.
2. Parkinsonism should remain a core feature of
PD, based upon a combination of cardinal mani-
festations. The criteria should include clear defi-
nitions of what constitutes each cardinal
manifestation, including explicit instructions for
examination.
3. The benchmark of diagnostic criteria should be
the expert clinical examination.
4. Criteria should incorporate both negative features
(that argue against diagnosis) and positive fea-
tures (that argue for diagnosis).
5. Criteria should be weighted, so that features that
are highly specific for alternate conditions are
differentiated from less specific “red flags.”
6. Criteria should incorporate a time component,
such that certainty can increase with longer dis-
ease duration, and individual diagnostic criteria
can be applied differentially in early versus late
disease.
7. Criteria should incorporate different levels of cer-
tainty, delineated as “clinical PD” (highly specific,
but not necessarily sensitive or representative) and
“possible PD” (balancing specificity and sensitivity).
8. Although ancillary diagnostic tests can be incorpo-
rated, only tests that have been extensively proven
as specific diagnostic markers in PD should be
included. Moreover, they should be considered as
ancillary only and not be essential to making
diagnosis.
Conclusion
In summary, advances in the field of PD have
strained our current definition of PD. This article is
meant to introduce the issue of PD redefinition and
provide preliminary proposals for how to advance.
Before the MDS task force creates formal diagnostic
criteria, we would like to enlist the input of our mem-
bers. To be part of the process, please visit the MDS
website and offer your ideas and feedback.
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